Exactech's go-private sale to TPG Capital, valued at $733 million, was approved by Exactech's shareholders, receiving favorable votes from 94.5% of shareholders that represent about 73.7% of outstanding common shares. The sale, which is set to be completed today, will make Exactech a private company and will stop trading of its common stock on the NASDAQ exchange.
Exactech's $733M sale to TPG secures shareholder approval
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.